Switch theme
Sign up to access all valuation multiples
Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.
1994
1.5K+
LTM Revenue $767M
LTM EBITDA $136M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yifan Pharmaceutical has a last 12-month revenue (LTM) of $767M and a last 12-month EBITDA of $136M.
In the most recent fiscal year, Yifan Pharmaceutical achieved revenue of $716M and an EBITDA of $110M.
Yifan Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yifan Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $767M | XXX | $716M | XXX | XXX | XXX |
| Gross Profit | $367M | XXX | $340M | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $136M | XXX | $110M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $71.2M | XXX | $83.9M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $70.7M | XXX | $53.6M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $110M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Yifan Pharmaceutical's stock price is CNY 13 (or $2).
Yifan Pharmaceutical has current market cap of CNY 16.0B (or $2.2B), and EV of CNY 17.4B (or $2.4B).
See Yifan Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.2B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Yifan Pharmaceutical has market cap of $2.2B and EV of $2.4B.
Yifan Pharmaceutical's trades at 3.4x EV/Revenue multiple, and 21.9x EV/EBITDA.
Equity research analysts estimate Yifan Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yifan Pharmaceutical has a P/E ratio of 31.5x.
See valuation multiples for Yifan Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 17.7x | XXX | 21.9x | XXX | XXX | XXX |
| EV/EBIT | 33.9x | XXX | 28.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.5x | XXX | 41.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1382.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialYifan Pharmaceutical's last 12 month revenue growth is 15%
Yifan Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Yifan Pharmaceutical's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yifan Pharmaceutical's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Yifan Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yifan Pharmaceutical acquired XXX companies to date.
Last acquisition by Yifan Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Yifan Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Yifan Pharmaceutical founded? | Yifan Pharmaceutical was founded in 1994. |
| Where is Yifan Pharmaceutical headquartered? | Yifan Pharmaceutical is headquartered in China. |
| How many employees does Yifan Pharmaceutical have? | As of today, Yifan Pharmaceutical has 1.5K+ employees. |
| Is Yifan Pharmaceutical publicy listed? | Yes, Yifan Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Yifan Pharmaceutical? | Yifan Pharmaceutical trades under 002019 ticker. |
| When did Yifan Pharmaceutical go public? | Yifan Pharmaceutical went public in 2004. |
| Who are competitors of Yifan Pharmaceutical? | Similar companies to Yifan Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Yifan Pharmaceutical? | Yifan Pharmaceutical's current market cap is $2.2B |
| What is the current revenue of Yifan Pharmaceutical? | Yifan Pharmaceutical's last 12 months revenue is $767M. |
| What is the current revenue growth of Yifan Pharmaceutical? | Yifan Pharmaceutical revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Yifan Pharmaceutical? | Current revenue multiple of Yifan Pharmaceutical is 3.1x. |
| Is Yifan Pharmaceutical profitable? | Yes, Yifan Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yifan Pharmaceutical? | Yifan Pharmaceutical's last 12 months EBITDA is $136M. |
| What is Yifan Pharmaceutical's EBITDA margin? | Yifan Pharmaceutical's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Yifan Pharmaceutical? | Current EBITDA multiple of Yifan Pharmaceutical is 17.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
